M2GEN Announces Collaboration with Microsoft to Advance Bioinformatics Solutions for Oncology

Bioinformatics company M2GEN announced a partnership with Microsoft in a move to improve and expand its data-driven solutions for research, discovery, and development of oncology therapies. The collaboration will combine M2GEN’s clinico-genomics database with Microsoft’s healthcare technologies to expand the possibilities of future cancer therapeutics.

High-quality data collection, healthcare expertise, and technological innovation are all necessary parts of unlocking the full potential of advanced analytics, big data, and machine learning. M2GEN’s position as the technological hub of the Oncology Research Information Exchange Network® puts the company in a strong position to accomplish these goals. M2GEN has been collecting a high-quality dataset consisting of germline genomic and tumor data combined with longitudinal clinical data from over 300,000 patients since 2014. The company has used that dataset to create a vital tool that efficiently delivers complex oncology analytics and data to pharmaceutical, biotech, and academia researchers. M2GEN’s work has led to breakthroughs in oncology science that improve cancer patient care.

M2GEN’s collaboration with Microsoft will allow the company to further enhance this tool, leveraging Azure Synapse Analytics with Microsoft Azure Healthcare APIs. This will enable broad and deep clinico-genomic services, capabilities, and analysis. The foundation of the platform will be built on Azure Purview and Azure Data Lake Storage Gen2. The technology team at M2GEN will be working directly with Microsoft’s engineers. The technology team is led by Chief Technology Officer Wilf Russel, who brings over 30 years of experience in software industry building.

M2GEN President and Chief Executive Officer Jim Gabriele outlined the importance of the partnership, noting that “Microsoft’s commitment to life science and its superior technologies make them a partner of choice for M2GEN. Together, our two companies will accelerate the impact of data and analytics on personalized cancer care for patients.” The two companies look forward to the benefits this partnership will provide for their ability to produce effective solutions for oncology research.

Read the full press release here.

See additional coverage in: